CD274 and neoplasm: The Food and Drug Administration (FDA) has approved anti‐PD‐1 and anti‐PD‐L1 antibodies for the treatment of tumors with high tumor mutation burden, microsatellite instability, abundant cytotoxic T lymphocyte infiltration, or increased PD‐L1 expression levels.37